Please ensure Javascript is enabled for purposes of website accessibility

This Is the Cheapest Coronavirus Vaccine Stock Right Now

By Adria Cimino - Mar 5, 2021 at 5:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

And let's take a look at the most overrated, the most promising, and the most under-the-radar coronavirus stocks too.

Coronavirus vaccine stocks haven't all shared the same fortunes. In this Motley Fool Live video recorded on Feb. 26, 2021, healthcare and cannabis bureau chief Corinne Cardina and contributor Adria Cimino discuss the most undervalued vaccine stock -- and vaccine stocks that have gained too much or too little investor attention.

Corinne Cardina: Let's do a quick little high-level summary. Of the COVID vaccine stocks that we are talking about today, which one would you say is the most undervalued at today's price?

Adria Cimino: The most undervalued, I would say is Pfizer (PFE -0.23%). The stock price is little changed last year, down 8% so far this year. It trades at 10 times forward earnings, which is the lowest in about a year. So I'd say Pfizer.

Corinne Cardina: Awesome. What would you say is the most overrated COVID vaccine stock?

Adria Cimino: I'd have to say Ocugen (OCGN 6.61%), because as we mentioned, we really don't know what's going to happen with Covaxin, and the shares are up 300% since the start of the year. It's little bit too much too soon for me.

Corinne Cardina: Totally. The most promising COVID vaccine stock for long-term investors.

Adria Cimino: I'd say Novavax (NVAX 11.12%). I think Novavax always seems to stay ahead of the game. They're always the first to announce. They announced last year they were going to investigate a combined flu and COVID vaccine, and they really have the expertise to do so. Now they're moving quickly into the strain-specific booster, investigating that. So I think Novavax.

Corinne Cardina: Awesome. My last one for this lightning round is: What would you say is the dark horse COVID vaccine stock for investors to watch?

Adria Cimino: I think it's maybe Vaxart (VXRT 7.14%). People have lost faith because of the whole neutralizing antibodies thing. But I think it's possible they could surprise us if the T-cells turn out to be able to handle coronavirus alone or if they figure out their booster shot -- I should say booster dose, because it's an oral vaccine -- works. That could be something that could definitely be the dark horse. But still, again, remain cautious. It's a risky stock.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$52.31 (-0.23%) $0.12
Novavax, Inc. Stock Quote
Novavax, Inc.
$57.15 (11.12%) $5.72
Vaxart, Inc. Stock Quote
Vaxart, Inc.
$3.75 (7.14%) $0.25
Ocugen, Inc. Stock Quote
Ocugen, Inc.
$2.42 (6.61%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.